Antiphospholipid syndrome (APS): Where does it come from?

Best Practice and Research: Clinical Rheumatology

Volumn 21, Issue 6, 2007, Pages 1071-1078

  Sherer, Yaniv ^a   Blank, Miri ^a   Shoenfeld, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

antiphospholipid syndrome; beta 2 glycoprotein I; infections; molecular mimicry

Indexed keywords

ACTIVATED PROTEIN C; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CHLORPROMAZINE; COMPLEMENT COMPONENT C3; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPITOPE; HLA ANTIGEN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERCELLULAR ADHESION MOLECULE 1; PHOSPHOLIPID ANTIBODY; PROCAINAMIDE; VASCULAR CELL ADHESION MOLECULE 1;

ACTIVE IMMUNIZATION; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; BLOOD CLOTTING; CHICKENPOX; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HEPATITIS C; HEPATITIS C VIRUS; HEREDITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; INFECTION; INJURY; MOLECULAR MIMICRY; NONHUMAN; PARVOVIRUS; PARVOVIRUS INFECTION; PASSIVE IMMUNIZATION; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT ABORTION; REVIEW; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; VARICELLA ZOSTER VIRUS; VEIN THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNITY; BETA 2-GLYCOPROTEIN I; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR MIMICRY; RISK FACTORS;

EID: 36649015106     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2007.09.005     Document Type: Review

References (43)

1. Asherson R.A., Cervera R., Piette J.C., et al. Milestones in the antiphospholipid syndrome. In: Asherson R.A., Cervera R., and Piette J.C. (Eds). The antiphospholipid syndrome II - autoimmune thrombosis (2002), Elsevier, Amsterdam
2. Sherer Y., and Shoenfeld Y. The antiphospholipid syndrome- an entity to be expanded. American Journal of Reproductive Immunology 41 (1999) 113-116
3. Twig G., Sherer Y., Blank M., et al. Antiphospholipid syndrome- pathophysiology. In: Carp H.J.A. (Ed). Recurrent pregnancy loss- causes, controversies and treatment (2007), Informa, London, UK 107-113
4. Blank M., Cohen J., Toder V., et al. Induction of antiphospholipid syndrome in naïve mice with mouse lupus monoclonal and human poly-clonal antiphospholipid antibodies. Proceedings of the National Academy of Sciences of the United States of America 88 (1991) 3069-3073
5. Kruase I., Leibovici L., Blank M., et al. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus 16 (2007) 176-180
6. Blank M., and Shoenfeld Y. Antiphospholipid syndrome infectious origin. Journal of Clinical Immunology 24 (2004) 12-23
7. Levy Y., Almog O., Gorshtein A., et al. The environment and antiphospholipid syndrome. Lupus 15 (2006) 784-790
8. Uthman I.W., and Gharavi A.E. Viral infections and antiphospholipid antibodies. Seminars in Arthritis and Rheumatism 31 (2002) 256-263
9. Dalekos G.N., Zachou K., and Liaskos C. The antiphospholipid syndrome and infection. Current Rheumatology Reports 3 (2001) 277-285
10. Orts J., Colomina A., Zuniga A., et al. Cytomegalovirus infection and antiphospholipid syndrome in humans. Arthritis & Rheumatism 48 (2003) 3296-3297
11. Asano Y., Sarukawa M., Idezuki T., et al. Multiple small pulmonary emboli associated with transient antiphospholipid syndrome in human Parvovirus B19 infection. Clinical Rheumatology 25 (2006) 585-587
12. Reitblat T., Drogenikov T., Sigalov I., et al. Transient anti-cardiolipin antibody syndrome in a patient with parvovirus B19 infection. American Journal of Medicine 109 (2000) 512-513
13. Guerin J., and Feighery E.C. Anti-beta-2-glycoprotein-I antibody isotype and IgG subclass in antiphospholipid syndrome patients. Autoimmunity 31 (1999) 109-116
14. Guglielmone H., Vitozzi S., Elbarcha O., et al. Cofactor dependence and isotype distribution of anticardiolipin antibodies in viral infections. Annals of the Rheumatic Diseases 60 (2001) 500-504
15. Espinosa G., Cervera R., and Asherson R.A. Catastrophic antiphospholipid syndrome and sepsis: a common link?. The Journal of Rheumatology 34 (2007) 923-926
16. Asherson R.A. The catarstrophic antiphospholipid syndrome. The Journal of Rheumatology 19 (1992) 508-512
17. Blank M., and Shoenfeld Y. Beta-2-glycoprotein-I, infections, antiphospholipid syndrome and therapeutic considerations. Clinical Immunology 112 (2004) 190-199
18. Shoenfeld Y., Krause I., Kvapil F., et al. Prevalence and clinical correlations of antibodies against six beta-2-glycoprotein-I related peptides in the antiphospholipid syndrome. Journal of Clinical Immunology 23 (2003) 377-383
19. Blank M., Shoenfeld Y., Cabilly S., et al. Prevention of antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proceedings of the National Academy of Sciences of the United States of America 96 (1999) 5164-5168
20. Blank M., Krause I., Fridkin M., et al. Bacterial induction of autoantibodies to beta-2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. The Journal of Clinical Investigation 109 (2002) 797-804
21. Gharavi A.E., Pierangeli S.S., Espinola R.G., et al. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis & Rheumatism 46 (2002) 545-552
22. Gharavi E.E., Chaimovich H., Cucurull E., et al. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus 8 (1999) 449-455
23. Shoenfeld Y., Aharon-Maor A., and Sherer Y. Vaccination as an additional player in the mosaic of autoimmunity. Clinical and Experimental Rheumatology 18 (2000) 181-184
24. Martinuc P.J., Avcin T., Bozic B., et al. Anti-phospholipid antibodies following vaccination with recombinant hepatitis B vaccine. Clinical and Experimental Immunology 142 (2005) 377-380
25. Mormile R., D'Alterio V., Treccagnoli G., et al. Henoch-Schonlein purpura with antiphospholipid antibodies after influenza vaccination: how fearful is it in children?. Vaccine 23 (2004) 567-568
26. Lillicrap D.P., Pinto M., Benford K., et al. Heterogeneity of laboratory test results for antiphospholipid antibodies in patients treated with chlorpromazine and other phenothiazines. American Journal of Clinical Pathology 93 (1990) 771-775
27. Merrill J.T., Shen C., Gugnani M., et al. High prevalence of antiphospholipid antibodies in patients taking procainamide. The Journal of Rheumatology 24 (1997) 1083-1088
28. de Groot P.G., Horbach D.A., and Derksen R.H. Protein C and other cofactors involved in the binding of antiphospholipid antibodies: relation to the pathogenesis of thrombosis. Lupus 5 (1996) 488-493
29. Pengo V., Biasiolo A., Brocco T., et al. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thrombosis and Haemostasis 75 (1996) 721-724
30. Cuadrado M.J., Lopez-Pedrera C., Khamashta M.A., et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis & Rheumatism 40 (1997) 834-841
31. Reverter J.C., Tassies D., Font J., et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis & Rheumatism 41 (1998) 1420-1427
32. Font J., Espinosa G., Tassies D., et al. Effects of beta2-glycoprotein I and monoclonal anticardiolipin antibodies in platelet interaction with subendothelium under flow conditions. Arthritis & Rheumatism 46 (2002) 3283-3289
33. Kornberg A., Renaudineau Y., Blank M., et al. Anti-beta 2-glycoprotein I antibodies and anti-endothelial cell antibodies induce tissue factor in endothelial cells. The Israel Medical Association Journal 2 supplement (2000) 27-31
34. Meroni P.L., Raschi E., Camera M., et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestations of the syndrome. Journal of Autoimmunity 15 (2000) 237-240
35. Lellouche F., Martinuzzo M., Said P., et al. Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 78 (1991) 2894-2899
36. Fishman P., Falach-Vaknin E., Sredni B., et al. Aspirin-interleukin-3 interrelationships in patients with anti-phospholipid syndrome. American Journal of Reproductive Immunology 35 (1996) 80-84
37. Fishman P., Falach-Vaknin E., Sredni B., et al. Aspirin modulates interleukin-3 production: additional explanation for the preventive effects of aspirin in antiphospholipid antibody syndrome. The Journal of Rheumatology 22 (1995) 1086-1090
38. Ornoy A., Yacobi S., Matalon S.T., et al. The effects of antiphospholipid antibodies obtained from women with SLE/APS and associated pregnancy loss on rat embryos and placental explants in culture. Lupus 12 (2003) 573-578
39. Matalon S.T., Shoenfeld Y., Blank M., et al. Antiphosphatidylserine antibodies affect rat yolk sacs in culture: a mechanism for fetal loss in antiphospholipid syndrome. American Journal of Reproductive Immunology 51 (2004) 144-151
40. Bernstein P.S., and Divon M.Y. Etiologies of fetal growth restriction. Clinical Obstetrics and Gynecology 40 (1997) 723-729
41. Holers V.M., Girardi G., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. The Journal of Experimental Medicine 195 (2002) 211-220
42. Girardi G., Berman J., Redecha P., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. The Journal of Clinical Investigation 112 (2003) 1639-1641
43. Sherer Y., Levy Y., and Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology 39 (2000) 421-426